Adding TQA3605 to standard hepatitis B treatment
Treatments studied
Part of Digestive system, Infections clinical trials.
This study tests whether adding a new medicine (TQA3605) to the usual hepatitis B treatment (nucleoside analogues) can better control the virus in people who still have low levels of the virus despite treatment. It aims to see if the combination is more effective than continuing the standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been taking hepatitis B medications (like entecavir, tenofovir, or similar) for at least a year, with no breaks longer than 15 days in the last 6 months.
- You have had chronic hepatitis B for more than a year.
- Your last blood test (within 30 days) showed a low but detectable amount of the virus (HBV DNA > 50 IU/mL).
- You are positive for HBeAg (a marker of active infection).
- You do not have other serious liver diseases, cirrhosis, liver cancer, or other significant health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called ZM-H1505R for people with chronic hepatitis B who are already taking standard antiviral therapy. It aims to see if the new drug can help control the infection better.
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
This study tests a two-step approach for chronic hepatitis B: first a shot called AHB-137, followed by another shot called TVAX-008. The goal is to see if this combination can help control the virus better.
This study tests a new drug, GST-HG131, for people with chronic hepatitis B who are already on stable treatment. It aims to see if the drug is safe and reduces the virus further.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.